Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review

Elliott, Jesse; Kelly, Shannon; Johnston, Amy; Skidmore, Becky; Gomes, Tara; Wells, George A.

doi:10.9778/cmajo.20160066

Cited by 22 publications

(14 citation statements)

References 38 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-IgE therapy could improve tolerability to AIT in patients with moderate-to-severe asthma. [ 191 ] If the patient is considered a candidate for AIT, referral to an allergist is recommended to explore this option further.…”

Section: Section 6: Pharmacological Management In Adults and Adolescementioning

confidence: 99%

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2021

View full text Add to dashboard Cite

The Saudi Initiative for Asthma 2021 (SINA-2021) is the fifth version of asthma guidelines for the diagnosis and management of asthma for adults and children, which is developed by the SINA group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up to date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is aligned for age groups: adults, adolescents, children aged 5–12 years, and children aged less than 5 years. SINA guidelines have focused more on personalized approaches reflecting better understanding of disease heterogeneity with the integration of recommendations related to biologic agents, evidence-based updates on treatment, and the role of immunotherapy in management. Medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and the current situation at national and regional levels. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.

show abstract

Section: Section 6: Pharmacological Management In Adults and Adolescementioning

confidence: 99%

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Omalizumab could improve tolerability to AIT in patients with moderate-to-severe asthma. [173] If the patient is considered a candidate for AIT, referral to an allergist is recommended to explore this option further.…”

Section: Pharmacological Management In Adults and Adolescentmentioning

confidence: 99%

The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2019

View full text Add to dashboard Cite

This is the fourth version of the updated guidelines for the diagnosis and management of asthma, developed by the Saudi Initiative for Asthma (SINA) group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up to date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is now more aligned for different age groups. The guidelines have focused more on personalized approaches reflecting better understanding of disease heterogeneity with integration of recommendations related to biologic agents, evidence-based updates on treatment, and role of immunotherapy in management. The medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and current situation at national and regional levels. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.

show abstract

“…Several evidence-based reviews and meta-analysis recently published corroborated the improvement in asthma symptoms and medication use with SCIT treatment [6,67,74,[76][77][78][79][80][81][82][83] although a lack of homogeneity have been found with regard to the SCIT effect on exacerbations and bronchial responsiveness in comparison to placebo or symptomatic treatment. The lack of uniformity in these analyses can be explained by the heterogeneity in study design and reporting of outcomes, a lack of universally accepted end points, minimal clinically important difference estimates, and differences in the efficacy of allergen preparations in different trials.…”

Section: Does the Use Of Scit Reduce Asthma Symptoms Asthma Exacerbations And Asthma Medication In Comparison To Placebo Or Symptomatic Tmentioning

confidence: 99%

Recent Advances in Allergen-Specific Immunotherapy as Treatment for Allergic Asthma: A Practical Overview

Tabar

Delgado

González-Mancebo

et al. 2021

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The Global Initiative for Asthma Report updated in 2019 stated that potential benefits of allergen immunotherapy (AIT), compared to pharmacological and avoidance options, must be weighed against the risk of adverse effects and the inconvenience and cost of the prolonged course of therapy in asthma. Thus, with the aim of clarifying some aspects with regard to the possible use of AIT in allergic asthma treatment armamentarium, a group of expert allergists from the Spanish Allergy and Clinical Immunology Scientific Society (SEAIC), particularly from the Immunotherapy and Asthma Interest Groups developed a frequently asked questions in clinical practice. This document updates relevant topics on the use of AIT in asthma and could facilitate physician clinical decisions and improve health outcomes for individual patients.

show abstract

Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review

Cited by 22 publications

References 38 publications

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children

The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children

Recent Advances in Allergen-Specific Immunotherapy as Treatment for Allergic Asthma: A Practical Overview

Contact Info

Product

Resources

About